Sven Hoffner Selected Research

Rifampin (Rifampicin)

1/2018	Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.
10/2016	Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
1/2014	High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients.
12/2013	Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.
6/2013	Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
5/2011	Direct nitrate reductase assay versus microscopic observation drug susceptibility test for rapid detection of MDR-TB in Uganda.
5/2009	Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis.
7/2008	The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
1/2005	A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sven Hoffner Research Topics

Disease

34	Tuberculosis (Tuberculoses) 01/2022 - 06/2002
15	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2021 - 05/2008
8	Extensively Drug-Resistant Tuberculosis 07/2020 - 02/2008
4	Infections 01/2022 - 01/2011
4	Multiple Organ Failure (MODS) 10/2013 - 05/2009
3	Pulmonary Tuberculosis 11/2021 - 06/2009
2	Reinfection 12/2021 - 07/2021
2	HIV Infections (HIV Infection) 01/2007 - 05/2002
1	Coinfection 12/2021
1	Genomic Instability 01/2011
1	Infection with Mycobacterium marinum 01/2011
1	Persistent Infection 01/2011

Drug/Important Bio-Agent (IBA)

38	Pharmaceutical PreparationsIBA 12/2021 - 05/2002
10	Isoniazid (Ftivazide)FDA LinkGeneric 01/2018 - 06/2002
9	Rifampin (Rifampicin)FDA LinkGeneric 01/2018 - 01/2005
7	FluoroquinolonesIBA 06/2020 - 08/2013
6	Pyrazinamide FDA LinkGeneric 12/2021 - 01/2005
5	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2011
3	Moxifloxacin (Avelox)FDA Link 01/2021 - 01/2014
3	Nitrate ReductaseIBA 09/2013 - 05/2009
2	Antitubercular AgentsIBA 04/2017 - 12/2016
2	bedaquiline (R207910)IBA 12/2016 - 01/2005
2	EnzymesIBA 01/2014 - 01/2011
2	Indicators and Reagents (Reagents)IBA 09/2013 - 02/2008
1	Levofloxacin (Levaquin)FDA Link 01/2021
1	Ofloxacin (Ofloxacine)FDA LinkGeneric 01/2018
1	DiarylquinolinesIBA 12/2016
1	AgarIBA 12/2016
1	ebselenIBA 06/2016
1	DNA GyraseIBA 01/2014
1	Adenosine Triphosphatases (ATPase)IBA 01/2014
1	Mycolic Acids (Mycolic Acid)IBA 04/2012
1	arabinogalactanIBA 04/2012
1	ethyl 4-methoxycinnamateIBA 07/2011
1	EicosanoidsIBA 01/2011
1	leukotriene A4 hydrolaseIBA 01/2011
1	DNA (Deoxyribonucleic Acid)IBA 12/2010
1	resazurinIBA 10/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2009
1	natural resistance-associated macrophage protein 1IBA 08/2009
1	Calcitriol Receptors (Calcitriol Receptor)IBA 08/2009
1	malachite greenIBA 02/2008
1	Coloring Agents (Dyes)IBA 02/2008
1	Antimicrobial PeptidesIBA 07/2006
1	streptolysin OIBA 07/2006
1	Proteins (Proteins, Gene)FDA Link 07/2006

Therapy/Procedure

4	Injections 12/2016 - 08/2013
3	Therapeutics 12/2017 - 06/2009